FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLCByoung Chul Cho, Tony Mok, Yi‐Long Wu et al.|Journal of Thoracic Oncology|2021Cited by 28
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrenceKevin J. Harrington, Christophe Le Tourneau, Lisa Licitra et al.|Oral Oncology|2023Cited by 17